Find out how higher dose aflibercept may reduce injection burden while preserving vision in retinal vasculopathy.

South Korea: In a post hoc analysis of the randomized PULSAR trial, aflibercept 8 mg demonstrated noninferior visual outcomes ...

The most-read ophthalmology biosimilar stories of 2025 included FDA approvals and real-world data. The continued expansion of ...

Bioeq AG will be responsible for the development, manufacturing, regulatory registration and ongoing supply of the biosimilar product.

In July 2025, Novartis Pharmaceuticals conducted a study is to assess the effect of Iptacopan to prevent conversion of early ...

Zydus Lifesciences has partnered with Swiss firm Bioeq to commercialise NUFYMCO in the US following FDA approval on December ...

GLP-1 medications like semaglutide in Ozempic and Wegovy help people lose weight. But they need to be taken for years, ...

According to the settlement agreement, the proposed biosimilar to Eylea® (aflibercept) can be marketed in the U.S., if approved by the FDA, in ...

Kalaris Therapeutics, Inc. reported improved Q3'25 results, with a net loss of $11.9M and $77M in cash. Click here to read why KLRS stock is a Buy.

Ollin Biosciences, Inc. (Ollin), a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases, today announced that Jason ...

Kalaris Therapeutics ( ($KLRS) ) has issued an announcement. On December 17, 2025, Kalaris Therapeutics announced it had entered into a securities ...

Kalaris Therapeutics ( ($KLRS) ) just unveiled an announcement. Kalaris Therapeutics announced on December 17, 2025, positive initial data from ...